Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 15, 2014 - Issue 7
Submit an article Journal homepage
464
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS)

Andreas SchreinerMedical & Scientific Affairs EMEA, Janssen-Cilag GmbH, Neuss, GermanyCorrespondence[email protected]
,
Anders SvenssonMedical Affairs EMEA, Janssen-Cilag AB, Sollentuna, Sweden
,
Robert WapenaarBiometrics and Reporting, Janssen-Cilag BV, Tilburg, The Netherlands
,
Pierre CherubinMedical Affairs EMEA, Janssen-Cilag, Issy-les-Moulineaux, France
,
Patricia PrincetCentre Hospitalier Spécialisé de Fains-Véel, Fains-Véel, France
,
Larisa SerazetdinovaFederal Institution of Healthcare Psychoneurologic Dispensary No. 5, Saint Petersburg, Russia
&
Mathias ZinkCentral Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
 show all
Pages 534-545 | Received 19 Nov 2013, Accepted 06 Mar 2014, Published online: 29 Apr 2014

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Weibo Zhang, Siyuan He, Liam Wilson, Astrid Foix-Colonier, Maud Pacou, Youwei Zhu, Yi Zhu, Lili Xue, Yanfeng Wang, Junmei Li, Yanli Liu & Jun Cai. (2023) Factors Influencing Patient and Caregiver Preferences for Antipsychotic Treatment of Schizophrenia in China: A Discrete Choice Experiment. Patient Preference and Adherence 17, pages 1421-1430.
Read now
Maryia Zhdanava, H Lynn Starr, Patrick Lefebvre, Todor I Totev, Aditi Shah, Kristy Sheng & Dominic Pilon. (2022) Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey. Neuropsychiatric Disease and Treatment 18, pages 1479-1493.
Read now
King-Teh Lee, Jin-Jia Lin & Hon-Yi Shi. (2018) Anxiety and depression are associated with long-term outcomes of hepatocellular carcinoma: A nationwide study of a cohort from Taiwan. The World Journal of Biological Psychiatry 19:6, pages 431-439.
Read now
Takefumi Suzuki. (2016) A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opinion on Drug Delivery 13:2, pages 253-264.
Read now

Articles from other publishers (12)

Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Claus Wolff-Menzler, Jörg Mahlich, Kerstin Olbrich, Adrian Wilk & Antonie Wimmer. (2021) Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antipsychotika. Gesundheitsökonomie & Qualitätsmanagement 26:06, pages 302-309.
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical Drug Investigation 40:4, pages 355-375.
Crossref
M.V. Kurmyshev, M.S. Zaytseva, A.Yu. Kuzmenko & A.N. Khannanova. (2020) The use of long acting antipsychotics in outpatient care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 77.
Crossref
Philip D. Harvey, Martin T. Strassnig & Juliet Silberstein. (2019) Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. Journal of Experimental Psychopathology 10:3, pages 204380871986569.
Crossref
Paola Bozzatello, Silvio Bellino, Irene Mancini, Luisa Sandei, Enrico Zanalda & Paola Rocca. (2018) Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clinical Drug Investigation 39:2, pages 169-178.
Crossref
Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U. Correll & Klaus Wiedemann. (2018) Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry 18:1.
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, Mark Olfson, John M Kane & Christoph U Correll. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin 44:3, pages 603-619.
Crossref
Frédéric LimosinDrifa BelhadiDenis CometMaud PacouSophie BoujuKristel Van ImpePascal Guillon. (2018) Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients. Journal of Clinical Psychopharmacology 38:1, pages 19-26.
Crossref
Andreas Schreiner, Asaf Caspi, Paul Bergmans, Pierre Cherubin, Sofia Keim, Elsa Lara, Irina Pinchuk, Daniel Schuepbach, Sajid Suleman & Ludger Hargarter. (2016) Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. Psychopharmacology 234:1, pages 3-13.
Crossref
Juan J. Fernández-Miranda, Victoria Caramés-García & Arantxa Sánchez-García. (2015) Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia. Journal of Clinical Psychopharmacology 35:6, pages 630-634.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.